BeOne Medicines (BEIGF) Return on Capital Employed (2016 - 2026)
BeOne Medicines (BEIGF) reported Return on Capital Employed of 10.46% for Q1 2026, up 1805.0% year-over-year from 0.55% in Q1 2025, and up 42.23% quarter-over-quarter from 7.35% in Q4 2025.
BeOne Medicines (BEIGF) Return on Capital Employed (2016 - 2026) Analysis & Trends
BeOne Medicines (BEIGF) has 11 years of Return on Capital Employed data on file, last reported at 10.46% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 10.46%, up 1805.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 10.46% (up 1805.0% YoY), and the FY2025 annual result was 8.56%, up 2413.0% from the prior year.
- Return on Capital Employed climbed to 10.46% in Q1 2026 per BEIGF's latest filing, from 7.35% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 10.46% in Q1 2026 and troughed at 38.47% in Q1 2023.
- A 5-year average of 17.94% and a median of 20.04% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed plunged 2177 bps in 2022, then soared 2727 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 34.51% in 2022, then rose by 9 bps to 31.33% in 2023, then soared by 50 bps to 15.52% in 2024, then soared by 147 bps to 7.35% in 2025, then soared by 42 bps to 10.46% in 2026.
- Business Quant data shows BEIGF's Return on Capital Employed at 10.46% in Q1 2026, 7.35% in Q4 2025, and 3.97% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | -50.43% |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 10.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.46% |
| Dec 31, 2025 | 7.35% |
| Sep 30, 2025 | 3.97% |
| Jun 30, 2025 | -2.61% |
| Mar 31, 2025 | -7.59% |
| Dec 31, 2024 | -15.52% |
| Sep 30, 2024 | -23.29% |
| Jun 30, 2024 | -23.63% |
| Mar 31, 2024 | -28.48% |
| Dec 31, 2023 | -31.33% |
| Sep 30, 2023 | -29.76% |
| Jun 30, 2023 | -35.99% |
| Mar 31, 2023 | -38.47% |
| Dec 31, 2022 | -34.51% |
| Sep 30, 2022 | -20.04% |
| Jun 30, 2022 | -18.32% |
| Mar 31, 2022 | -17.24% |
| Dec 31, 2021 | -12.74% |
| Sep 30, 2021 | -32.97% |
| Jun 30, 2021 | -30.01% |